Quantitative Computed Tomography in Progressive Pulmonary Fibrosis: Data from a Sub-Study of the Double Blind, Randomized, Placebo-controlled INBUILD Trial.

Anand Devaraj^1,2,3, Peter M George^1,2,3, Olivier Joly³, Jonathan Goldin^4,5, Eric S White⁶, Carina Ittrich⁷, Susanne Stowasser⁸, Frank Risse⁷

¹Royal Brompton Hospital, London, United Kingdom.

²National Heart and Lung Institute, Imperial College London, London, United Kingdom.

³Brainomix, Oxford, United Kingdom.

⁴Departments of Radiology and Medicine, University of California Los Angeles (UCLA) David Geffen School of Medicine, Los Angeles, California, USA.

⁵Voiant Clinical LLC, Boston, Massachusetts, USA.

⁶Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA.

⁷Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.

PubMed DOI

Abstract

RATIONALE: Change in forced vital capacity (FVC) is an established endpoint in clinical trials in lung fibrosis, but more sensitive measures of structural deterioration are needed. Quantitative computed tomography (QCT) measurements predict FVC decline and mortality, but more information is needed on their prognostic value and response to therapy. OBJECTIVES: Evaluate the prognostic potential of…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.